SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD
SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Nephrology Consultation — Booker T. Washington
| Patient | Booker T. Washington |
|---|
| Date of birth | 1967-04-05 |
|---|
| Identifiers | MRN HR-NI017-SYN; SSN (made up) 000-17-2284 |
|---|
| Document date | 2026-05-11 |
|---|
| Author | Desmond Oyelaran, MD |
|---|
| Custodian | St. Posthumous Health Center |
|---|
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Reason for Referral
Severe hypertension with chronic kidney disease stage G3b and severely increased albuminuria in a 59-year-old man. Please assess the cause of the kidney disease, advise on kidney-protective therapy and blood pressure targets, and share his long-term care. [S]
Urgency: Soon, within one week; kidney ultrasound and echocardiogram booked for the morning of the consultation. [S]
Questions for the consultant:
- Is this hypertensive nephrosclerosis, or does anything point to another kidney disease or a secondary cause of hypertension that needs testing?
- Do you agree with titrating losartan to the maximum dose and adding an SGLT2 inhibitor, and how much rise in creatinine should we accept?
- What blood pressure target should we aim for, and which agent should come next if he stays above it?
- Do his bicarbonate, PTH, and hemoglobin need treatment now?
- How often should we monitor, and when should he return to nephrology?
History of Present Illness
Mr. Washington is seen at the request of Dr. Whitfield one week after presenting with headaches, palpitations, fatigue, and a blood pressure of 212/128 mmHg. On amlodipine and losartan his home readings have fallen to the 160s and 170s over 100s, he has had one mild headache this week, and his palpitations are less frequent. He has had no chest pain, breathlessness, weakness, confusion, or sudden change in vision, and no lightheadedness on standing or ankle swelling. He gets up twice a night to urinate and has seen no blood in the urine. He takes no NSAIDs or other over-the-counter products. He travels often for work and wants a plan that he can keep on the road. [S]
Historical basis. These claims are historical evidence, not findings from a modern examination.
- Booker T. Washington was born into slavery on the James Burroughs plantation in Franklin County, Virginia, in 1856; the National Park Service timeline gives the date as April 5, 1856. [D]
- Washington wrote in Up from Slavery (1901) that he was not sure of the exact date of his birth and estimated the year as 1858 or 1859; the April 5, 1856 date traces to a report by his brother John after his death and was adopted by the Tuskegee trustees. [D]
- After emancipation in 1865 Washington moved with his mother, Jane, and his family to Malden, West Virginia, where he worked in the salt and coal mines; a National Park Service release gives his mother's death as 1876. [D]
- Washington opened Tuskegee Institute in Tuskegee, Alabama, on July 4, 1881, at age 25, and led it for the rest of his life; in March 1915 he sponsored National Negro Health Week. [D]
- In 1911 Washington was beaten in New York City and received two large gashes in his head and a torn ear, recovering without apparent sequelae; he had chronic indigestion, especially when traveling, and spent several days in 1911 at the Battle Creek Sanitarium. [D]
5 later historical claims are omitted because they describe events after the index age. See the teaching note.
Allergies and Intolerances
| Allergy | Reaction | Status | Evidence |
|---|
| No known allergy | | active | S |
Medications
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|
| Amlodipine 10 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-05-04 | active | S |
| Losartan 50 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-05-04 to 2026-05-11 | completed | S |
| Losartan 100 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-05-11 | active | S |
| Dapagliflozin 10 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-05-11 | active | S |
| Atorvastatin 20 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-05-04 | active | S |
Problems
| Problem | Clinical status | Verification | Code | Provenance |
| Severe hypertension with hypertensive kidney disease; synthetic modern diagnosis linked to the documented 1915 blood pressure of 220/150 | active | confirmed |
I12.9 | S — Synthetic active diagnosis for the teaching episode; the 1915 findings remain D and the retrospective diagnosis remains R. |
| Chronic kidney disease stage G3b A3 (severely increased albuminuria), attributed to hypertensive nephrosclerosis | active | confirmed |
N18.32 | S — Synthetic diagnosis supported by small echogenic kidneys and albuminuria; linked to the documented 1915 diagnosis of Bright's disease. |
| Hypertensive retinopathy, both eyes, without papilledema | active | confirmed |
H35.033 | S — Synthetic funduscopic finding that echoes the documented failing vision. |
| Mild anemia of chronic kidney disease, iron replete; monitor | active | confirmed |
D63.1 | S — Synthetic finding from the baseline hemoglobin and iron studies. |
| Hyperlipidemia | active | confirmed |
E78.5 | S — Synthetic finding from the baseline LDL cholesterol. |
Physical Exam
Vital signs recorded on 2026-05-11; see the referring visit's Vital Signs section. [S]
| System | Finding |
|---|
| General | Alert, articulate, and in no distress |
| Blood pressure | 172/104 mmHg, the average of two seated readings after five minutes of rest |
| Eyes | Arteriolar narrowing on undilated funduscopy; no hemorrhages or papilledema |
| Heart | Regular rhythm, rate 82; S4; no murmur |
| Lungs | Clear |
| Abdomen | No abdominal bruit |
| Extremities | No edema |
Results
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
| 2026-05-11 | Sodium [Moles/volume] in Serum or Plasma | 138 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-05-11 | Potassium [Moles/volume] in Serum or Plasma | 4.6 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-05-11 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 22 | mmol/L | 22-29 mmol/L | Normal | S |
| 2026-05-11 | Urea nitrogen [Mass/volume] in Serum or Plasma | 36 | mg/dL | 6-24 mg/dL | High | S |
| 2026-05-11 | Creatinine [Mass/volume] in Serum or Plasma | 2.2 | mg/dL | 0.74-1.35 mg/dL | High | S |
| 2026-05-11 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 34 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Low | S |
| 2026-05-11 | Glucose [Mass/volume] in Serum or Plasma | 95 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-05-11 | Left ventricular Ejection fraction | 60 | % | 50-70% | Normal | S |
Assessment
- Chronic kidney disease stage G3b A3 (N18.32). Small, echogenic, symmetric kidneys with severe hypertension, left ventricular hypertrophy, and hypertensive retinopathy fit long-standing hypertensive nephrosclerosis, and the disease is chronic, not acute. Albuminuria of 820 mg/g is high for nephrosclerosis alone, so the response to treatment is the test: a fall of at least 30 percent supports the diagnosis. One week after losartan, creatinine is 2.2 mg/dL (up 5 percent), eGFR 34, and potassium 4.6 mmol/L, so blockade can be pushed further. His risk of progression is very high. [S]
- Severe hypertension with hypertensive kidney disease (I12.9). 172/104 mmHg, improving but far above target. The symmetric kidneys, the absence of an abdominal bruit, and the small creatinine rise on losartan argue against renal artery stenosis, and his potassium is normal. Secondary causes need testing only if blood pressure stays above target on three agents including a diuretic. [S]
- Mild anemia of chronic kidney disease (D63.1). Hemoglobin 12.6 g/dL with ferritin 210 ng/mL and transferrin saturation 26 percent: iron replete, and well above any threshold for treatment. [S]
- Mineral and bone disorder and acid-base status of chronic kidney disease. PTH 92 pg/mL is mildly raised with normal calcium and phosphate, and bicarbonate 21 to 22 mmol/L is above the level that needs alkali. Neither needs treatment now. [S]
Data reviewed: Today's kidney ultrasound: both kidneys small (9.4 and 9.6 cm) and echogenic, symmetric, without hydronephrosis. Today's echocardiogram: concentric left ventricular hypertrophy, ejection fraction 60 percent. Last week's ECG and dilated funduscopic examination. Both basic metabolic panels, the urine albumin-creatinine ratio, mineral studies, blood count, and iron studies. No urinalysis with microscopy is on file. [S]
Plan of Treatment
- Increase losartan to 100 mg daily today and continue amlodipine 10 mg daily. [S]
- Start dapagliflozin 10 mg daily today: eGFR is above 20 and albuminuria above 200 mg/g. It is for kidney protection, so continue it even if eGFR later falls below 20. [S]
- Accept a creatinine rise of up to 30 percent from 2.1 mg/dL after these changes; check potassium and creatinine in about three weeks. [S]
- If blood pressure is still above target on full doses of losartan and amlodipine, add chlorthalidone 12.5 mg daily, which works at his level of kidney function. [S]
- Target a standardized office systolic pressure below 120 mmHg if tolerated, with below 130/80 as the first step. [S]
- Avoid NSAIDs; sick-day rule to hold losartan, dapagliflozin, and any diuretic on days with vomiting, diarrhea, or poor fluid intake. [S]
- Sodium below 2 g a day, with a plan for meals while traveling. [S]
- Urine albumin-creatinine ratio once the regimen is complete. Urinalysis with microscopy and further testing for other kidney diseases if albuminuria does not fall on treatment or kidney function changes unexpectedly. [S]
- Calcium, phosphate, PTH, and a baseline 25-hydroxyvitamin D at about six months; hemoglobin at least yearly. No alkali, vitamin D analog, or iron now. [S]
- Pneumococcal and hepatitis B vaccination for chronic kidney disease. [S]
- Calculate the kidney failure risk once eGFR has settled on full therapy. [S]
- Discussed with Dr. Whitfield in person today; the patient agrees with the plan. [S]
- Follow-up: Primary care will manage titration and monitoring on the CMID schedule, with eGFR and urine albumin about three times a year. Nephrology will review him with the six-month results and the kidney failure risk, and sooner for a creatinine rise of more than 30 percent, potassium above 5.5 mmol/L, blood pressure above target on three agents, or albuminuria that does not fall. [S]